



6 July 2005

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000
Dear Sir,

Expansion of Medical Advisory Board - Four Distinguished Experts as Members


Perth, Australia - Wednesday July 6, 2005 - Resonance Health Limited (ASX: RHT) announced today the expansion of its Medical Advisory Board. The board is now comprised of four of the most influential global opinion leaders in the "Iron Overload" disease area. This expanded board will have a significant impact on how Resonance Health and its lead commercial product, FerriScan[®], are viewed in the clinical community.

Dr James Williams, Managing Director of Resonance Health remarked, "We are proud to have four of the world's most respected clinicians as advisors to Resonance Health. Their extensive background in iron overload disorders combined with their many years of clinical expertise and leadership will undoubtedly be a valuable resource to Resonance Health".

Comprising **Dr Bruce Bacon** (addition), **Dr Kris Kowdley** (current), **Dr John Olynyk** (addition) and **Dr John Porter** (addition) the board will focus on assisting in the awareness and education program related to the commercial rollout of FerriScan. Additionally, the board will take a lead role in driving the scientific and clinical requirements for Resonance Health, along with participating in ongoing regulatory and reimbursement activities.

Dr Bruce R. Bacon MD is currently Director of the division of Gastroenterology and Hepatology at Saint Louis University School of Medicine, co-medical Director of the Saint Louis University Liver Center and serves as Chair of the CAQ Board on Transplant Hepatology. Dr Bacon's research has largely been in iron metabolism in the liver, and he was a member of the research team that discovered the gene that is abnormal in patients who have hereditary hemochromatosis. Previously he has served on the Board of Directors of the American Liver Foundation as Vice Chair for Medical Affairs. He was the 1999-2003 Chair of the ABIM Subspecialty Board for Gastroenterology and was the President of the American Association for the Study of Liver Diseases in 2004. Dr Bacon has written more than 240 original articles, reviews, and book chapters.

Dr Kris V. Kowdley A.B., MD FACP is Professor of Medicine in the division of Gastroenterology/Hepatology at the University of Washington, attending physician and Director of the Iron Overload Clinic at the University of Washington Medical Centre. He is an author of over 150 articles, book chapters and reviews on various topics in liver disease and serves on the editorial boards of the 'Journal of Clinical Gastroenterology and 'GI Endoscopy'. He is involved in several national committees. Dr Kowdley's research and clinical interests include hepatic iron overload disorders,



treatment of chronic viral hepatitis B and C, cholestatic liver diseases, non-alcoholic fatty liver disease and portal hypertension.

Dr John Olynyk BMedSc MBBS FRACP MD is Professor of Gastroenterology, School of Medicine and Pharmacology University of WA, Fremantle Hospital campus Fremantle WA, Australia. Dr Olynyk also holds the positions of Professor of Internal Medicine St. Louis University, St. Louis MO, USA and Deputy Director, Western Australian Institute of Medical Research Perth WA, Australia. He is an author of over 100 papers, book chapters and publications. Dr Olynyk's research and clinical interests include hepatic iron overload disorders, chronic liver disease, and non-invasive imaging techniques.

Dr John B. Porter MA, MD, FRCP, FRCPath is Professor of Haematology and Consultant Haematologist at University College London Hospitals. He was awarded FRCP from the Royal London College of Physicians London in 1995 and FRCPath in Haematology from the Royal College of Pathologists 1996. Dr Porter was awarded the Lionel Whitby Medal for MD of 'exceptional merit' at Cambridge University in 1999. Since 1999, Dr Porter has been Professor at the University College London. Dr Porter's main research interests centre around the treatment of thalassaemia and sickle cell disorders for which he receives funding from both the MRC and NIH.

Mr Glenn Smith, Marketing Director of Resonance Health said, "The company recognises the unique scientific, medical and target market insights of the expanded medical advisory board which will assist in continuing to develop Resonance Health as a worldwide brand and leader in innovative MRI based tests. The members of the Medical Advisory Board will be integral in our aim to establish FerriScan as the definitive tool for non-invasive liver iron measurement".


The expansion of the Medical Advisory Board sees Dr Christine Bennett resign her position on the former Inner Vision Biometrics Medical Advisory Board however, Dr Bennett remains as a non-executive director of Resonance Health Limited.

Further information:

About "Iron Overload" Conditions

Having too much iron in the body and being unable to get rid of this excess iron is one of the world's most common hereditary disorders with approximately 500 million people either carriers of the defective gene(s) or symptomatic.

The disorders, often collectively termed as "Iron Overload", are generally classified as primary (e.g. hereditary haemochromatosis - HHC) or secondary (e.g. acquired – transfusional iron overload such as thalassaemia). Approximately 11 million people globally, who have "clinically significant" iron loading, would benefit from improved diagnosis and management of their condition.



Haemochromatosis is a genetic disorder that causes iron deposition in the liver, and in other organs of the body, resulting in iron overload. The condition frequently remains undiagnosed because of lack of awareness, its long latency period and its non-specific symptoms. Thalassaemia, a genetic blood disorder and a very severe and debilitating form of anaemia, also results in iron overload due to the requirement for frequent blood transfusions.

Iron toxicity is a major cause of organ damage particularly in the:

Liver – fibrosis / cirrhosis;

Heart – congestive heart failure and arrhythmia and;

Pancreas – diabetes and arthritis of the joints.

About Resonance Health Ltd

Resonance Health Limited, through its wholly owned subsidiary Resonance Health Analysis Services (RHAS), continues to commercialise FerriScan, a non-invasive diagnostic test to measure the iron content of a patient’s liver to assist clinicians in the detection and treatment of iron overload disorders such as hereditary haemochromatosis and thalassaemia.

Traditional methods for diagnosing iron overload in the liver involve use of indirect blood markers and the removal of a biopsy sample from the liver. Neither of these tools are optimal for measurement of iron levels. Biopsies are invasive and dangerous, whilst both methods are inaccurate due to sample size or the indirect nature of the test.

FerriScan uses existing Magnetic Resonance Imaging (MRI) machines at radiology facilities worldwide to provide suitable scan images of the liver. The images are subsequently analysed at a centralised RHAS image analysis centre to quantify iron loading using proprietary software. The FerriScan test provides a safe and accurate alternative to traditional diagnostic methods.

FerriScan has received regulatory clearance to be marketed in the USA, Australia, U.K and Europe. Further information about Resonance Health and FerriScan can be obtained from the following web sites: www.resonancehealth.com and www.ferriscan.com

Media and Investor Relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M – 0422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director Resonance Health Limited T - +61 9286 5300 M - 0409 050 519 Email: jamesw@ferriscan.com